Latest Breaking News On - Prescribing informationincluding patient - Page 7 : comparemela.com

New England Journal of Medicine Publishes Positive Phase 3 Dupixent® (dupilumab) Results in Children with Moderate-to-severe Asthma

/PRNewswire/ Dupixent significantly reduced severe asthma attacks and improved lung function and asthma control in children aged 6 to 11 years with.

United statesFrance generalVanderbilt universityMonroe carell jrLeonardb bacharierGeorged yancopoulosRegeneron velocimmunePediatric asthma researchRegeneron pharmaceuticals incRegeneron genetics centerDupilumab development programRegeneron velocimmune technologyTeva pharmaceutical industries ltdExchange commissionEuropean unionEuropean medicines agency

Second Dupixent® (dupilumab) Phase 3 Eosinophilic Esophagitis Trial to Demonstrate Significant Disease Improvements, Underscoring Role of Type 2 Inflammation in This Complex Disease

/PRNewswire/ Dupixent 300 mg weekly significantly improved the ability to swallow and reduced eosinophils in the esophagus compared to placebo, reinforcing.

France generalGeorged yancopoulosNaimish patelRegeneron velocimmuneRegeneron pharmaceuticals incRegeneron genetics centerDrug administrationDupilumab development programRegeneron velocimmune technologyTeva pharmaceutical industries ltdExchange commissionMd head of global developmentDysphagia symptom questionnaireBreakthrough therapyChief scientific officerGlobal development

Dupixent® (dupilumab) is the First Biologic to Significantly Reduce Itch and Skin Lesions in Phase 3 Trial for Prurigo Nodularis, Demonstrating the Role of Type 2 Inflammation in this Disease

/PRNewswire/ Pivotal trial met primary and all key secondary endpoints Dupixent significantly reduced itch at 12 weeks, and nearly three times as many.

France generalUnited statesJohn reedGeorged yancopoulosRegeneron velocimmuneRegeneron pharmaceuticals incRegeneron genetics centerDupilumab development programRegeneron velocimmune technologyTeva pharmaceutical industries ltdExchange commissionGlobal head of researchChief scientific officerGlobal headWorst itch numeric rating scaleGlobal assessment

New Dupixent® (dupilumab) Data in Patients as Young as Six Years Old With Moderate-to-Severe Atopic Dermatitis to Be Presented at WCPD and EADV

New Dupixent® (dupilumab) Data in Patients as Young as Six Years Old With Moderate-to-Severe Atopic Dermatitis to Be Presented at WCPD and EADV
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

France generalJonathan silverbergYoko kataokaEric simpsonKen igawaGeorged yancopoulosRegeneron velocimmuneElaine siegfriedStephan weidingerAmy pallerDupilumab monotherapyAlisa beckAndreas wollenbergMichael wechslerCarlos ferrVenereology congress

Regeneron Pharmaceuticals : New Dupixent® (dupilumab) Data in Patients as Young as Six Years Old With Moderate-to-Severe Atopic Dermatitis to Be Presented at WCPD and EADV

Regeneron Pharmaceuticals : New Dupixent® (dupilumab) Data in Patients as Young as Six Years Old With Moderate-to-Severe Atopic Dermatitis to Be Presented at WCPD and EADV
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.